Market performance comparison in the vaccine sector was noted, alongside an upcoming August 5th FDA decision on a flu candidate.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market performance comparison in the vaccine sector was noted, alongside an upcoming August 5th FDA decision on a flu candidate.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novavax
company in Gaithersburg, Maryland
Nothing else this week.
-
Moderna
American biotechnology company
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
Related events
- Moderna, Merck, and the National Cancer Institute announced successful trial results for a combined cancer vaccine and immunotherapy program.
- GlaxoSmithKline, Moderna, and Sinovac are leveraging the influenza vaccine market, with Phase 3 trials showing strong immune responses.
- Analyst comments on industry trends regarding Moderna's competition in the cancer vaccine market.
- Lawsuit filed alleging Pfizer engaged in deceptive marketing regarding vaccine efficacy rates.
- Moderna and Merck announced a partnership on their mRNA cancer vaccine trial, leading to analyst rating hikes.